Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: Temporal changes and risk factors

Clinical Infectious Diseases

Volumn 51, Issue 8, 2010, Pages 947-956

  Puhan, Milo A ^a   Van Natta, Mark L ^a   Palella, Frank J ^b   Addessi, Adrienne ^c   Meinert, Curtis ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ARTICLE; CONFIDENCE INTERVAL; CYTOMEGALOVIRUS RETINITIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; UNITED STATES;

EID: 77957843595     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656415     Document Type: Article

References (16)

1. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300(1):51-59.
2. Ewings FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22(1):89-95.
3. Jaggy C, von Overbeck J, Ledergerber B, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362(9387):877-878.
4. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146(2):87-95.
5. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43(1):27-34.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al; HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338(13):853-860.
7. Smit C, Geskus R, Uitenbroek D, et al. Declining AIDS mortality in Amsterdam: contributions of declining HIV incidence and effective therapy. Epidemiology 2004; 15(5):536-542.
8. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology 2007; 114(4):780-786.
9. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD. Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology 2007; 114(4):787-793.
10. Centers for Disease Control and Prevention. National Vital Statistics System. http://www.cdc.gov/nchs/nvss.htm. Updated 9 August 2010. Accessed 26 August 2010.
11. Brenner H, Hakulinen T. On crude and age-adjusted relative survival rates. J Clin Epidemiol 2003; 56(12):1185-1191.
12. Dickman PC. Modeling of the cure fraction in survival studies. STATA Journal 2007; 7(3):1-25.
13. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004; 23(1):51-64.
14. Centers for Disease Control and Prevention. HIV surveillance report. http://www.cdc.gov/hiv/topics/surveillance/resources/reports. Updated 14 June 2010. Accessed 26 August 2010.
15. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360(9327):119-129. (Pubitemid 34786200)
16. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: results from the DAD study. AIDS 2003; 17(8):1179-1193.